Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital

  • Muangto, Teerapat (Department of Obstetrics and Gynecology, Faculty of Medicine, Thammasat University Hospital) ;
  • Chanthasenanont, Athita (Department of Obstetrics and Gynecology, Faculty of Medicine, Thammasat University Hospital) ;
  • Lertvutivivat, Supapen (Department of Obstetrics and Gynecology, Faculty of Medicine, Thammasat University Hospital) ;
  • Nanthakomon, Tongta (Department of Obstetrics and Gynecology, Faculty of Medicine, Thammasat University Hospital) ;
  • Pongrojpaw, Densak (Department of Obstetrics and Gynecology, Faculty of Medicine, Thammasat University Hospital) ;
  • Bhamarapravatana, Kornkarn (Department of Preclinical Science, Faculty of Medicine, Thammasat University Hospital) ;
  • Suwannarurk, Komsun (Department of Obstetrics and Gynecology, Faculty of Medicine, Thammasat University Hospital)
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

Background: Cervical cancer is the second most common of malignancy found in Thai women. Human papillomavirus (HPV) infection is a major cause. The objective of the present study was to evaluate the prevalence of HPV infection and association with abnormal cervical cytology in Thai women. Materials and Methods: This study was conducted at the Gynecologic Clinic, Thammasat University, Pathum Thani, Thailand. A total of 2,144 cases who underwent annual cervical cancer screening by co-testing (liquid based cytology and HPV testing, DNA versus mRNA) during the priod from July 2013 to June 2016 were recruited in this study. Results: Prevalence of positive high risk (HR) HPV DNA and mRNA test were 19.7 and 8.4%, respectively with a statistically significant difference. Majority of cases of abnormal cytology in this study were atypical squamous cells of undetermined significance (ASC-US). In patients with ASC-US, positive HR HPV DNA was greater than in the mRNA group (10.1 and 4.5%, p<0.001). Nonetheless, there was no significant difference in participants with cervical intraepithelial neoplasia (CIN). HPV mRNA test had slightly lower sensitivity but higher negative predictive value (NPV) than the DNA test to detect abnormal cytology during cervical cancer screening (p<0.001). Both HPV test (DNA and mRNA) had equally efficacy to detect high grade precancerous lesion or higher (CIN 2+). Conclusions: Prevalence of HR HPV DNA and mRNA were 19.7 and 8.4 percent, respectively. NPV of HPV mRNA was higher than DNA test. Both tests had equal efficacy to detect CIN 2+ with sensitivity and specificity of 63% vs 55.7% and 83% vs 92%, respectively.

Keywords

Acknowledgement

Supported by : Thammasat Hospital

References

  1. Anderson L, O'Rorke M, Jamison J, et al (2013). Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis. J Med Virol, 85, 295-308. https://doi.org/10.1002/jmv.23459
  2. Chansaenroj J, Lurchachaiwong W, Termrungruanglert W, et al (2010). Prevalence and genotypes of human papillomavirus among Thai women. Asian Pac J Cancer Prev, 11, 117-22.
  3. Chen X, Wallin KL, Duan M, et al (2015). Prevalence and genotype distribution of cervical human papillomavirus (HPV) among women in urban Tianjin, China. J Med Virol, 87, 1966-72. https://doi.org/10.1002/jmv.24248
  4. Luttmer R, Berkhof J, Dijkstra MG, et al (2015). Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNApositive women. J Clin Virol, 67, 59-66. https://doi.org/10.1016/j.jcv.2015.04.004
  5. Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, 359-86. https://doi.org/10.1002/ijc.29210
  6. Kantathavorn N, Mahidol C, Sritana N, et al (2015). Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs. Infect Agent Cancer, 10, 7-15. https://doi.org/10.1186/s13027-015-0001-5
  7. Laowahutanont P, Karalak A, Wongsena M, et al (2014). Prevalence of high risk human papillomavirus infection with different cervical cytological features among women undergoing health examination at the National Cancer Institute, Thailand. Asian Pac J Cancer Prev, 15, 5879-82. https://doi.org/10.7314/APJCP.2014.15.14.5879
  8. Lillsunde LG, Kaliffa M, Bergengrenb L, et al (2016). HPV Genotyping from the high risk mRNA Aptima assay- a direct approach using DNA from Aptima sample tubes. J Virol, 235, 80-4.
  9. Li H, Zhang J, Chen Z, et al (2013). Prevalence of human papillomavirus genotypes among women in Hunan province, China. Eur J Obstet Gynecol Reprod Biol, 170, 202-5. https://doi.org/10.1016/j.ejogrb.2013.05.010
  10. Luttmer R, Berkhof J, Dijkstra MG, et al (2015). Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNApositive women. J Clin Virol, 67, 59-66. https://doi.org/10.1016/j.jcv.2015.04.004
  11. Paengchit K, Kietpeerakool C, Lalitwongsa S (2014). Prevalence and genotype distribution of HPV among women attending a cervical cancer screening mobile unit in Lampang, Thailand. Asian Pac J Cancer Prev, 15, 6151-4. https://doi.org/10.7314/APJCP.2014.15.15.6151
  12. Preisler S, Rebolj M, Ejegod DM, et al (2016). Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study. BMC Cancer, 16, 510-22. https://doi.org/10.1186/s12885-016-2518-4
  13. Rebolj M, Lynge E, Ejegod D, et al (2014). Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology. Gynecol Oncol, 135, 474-80. https://doi.org/10.1016/j.ygyno.2014.10.014
  14. Tezcan S, Ozgur1 d, Ulger m, et al (2014). Human papillomavirus genotype distribution and E6/E7 oncogene expression in Turkish women with cervical cytological findings. Asian Pac J Cancer Prev, 15, 3997-4003. https://doi.org/10.7314/APJCP.2014.15.9.3997
  15. Ucakar V, Poljak M, Klavs I (2012). Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: a cervical cancer screening based study. Vaccine, 30, 116-20. https://doi.org/10.1016/j.vaccine.2011.10.066
  16. Westre B, Giske A, Guttormsen H, et al (2016). 5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions. BMC Clin Pathol, 16, 9-16. https://doi.org/10.1186/s12907-016-0032-x
  17. Zeng Z, Yang H, Li Z, et al (2016). Prevalence and genotype distribution of HPV infection in China: Analysis of 51,345 HPV genotyping results from China's largest CAP certified laboratory. J Cancer, 71, 1037-43.
  18. Zhao FH, Zhu FC, Chen W, et al (2014). Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Int J Cancer, 135, 2604-11. https://doi.org/10.1002/ijc.28896